<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pigment epithelium-derived factor (PEDF) recombinant protein has been investigated in many kinds of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> due to its potent antiangiogenic activity </plain></SENT>
<SENT sid="1" pm="."><plain>However, the complexity of protein purification, instability of recombinant protein and requirement of repeated injections are obstacles for the recombinant PEDF therapy for <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We successfully synthesized <z:chebi fb="1" ids="46793">polyethyleneglycol</z:chebi>-polyetherimide (<z:chebi fb="77" ids="46793">PEG</z:chebi>-<z:chebi fb="0" ids="53231">PEI</z:chebi>) and cRGD-<z:chebi fb="77" ids="46793">PEG</z:chebi>-<z:chebi fb="0" ids="53231">PEI</z:chebi> which was coupled with a cyclic RGD <z:chebi fb="7" ids="16670">peptide</z:chebi>, a special ligand for integrin αvβ3 receptor, as the vehicle for PEDF gene therapy in this study </plain></SENT>
<SENT sid="3" pm="."><plain>In vitro, the competitive binding assay showed that cRGD contributed to the enhanced gene transfection efficiency of <z:chebi fb="77" ids="46793">PEG</z:chebi>-<z:chebi fb="0" ids="53231">PEI</z:chebi> in human umbilical vein endothelial cells (HUVECs) </plain></SENT>
<SENT sid="4" pm="."><plain>PEDF gene delivered by cRGD-<z:chebi fb="77" ids="46793">PEG</z:chebi>-<z:chebi fb="0" ids="53231">PEI</z:chebi> apparently suppressed growth of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> with a 67.4% reduction and decreased microvessel density in <z:mp ids='MP_0003815'>nude</z:mp> mice bearing SW620 human colorectal xenografts </plain></SENT>
<SENT sid="5" pm="."><plain>Accordingly, SW620 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from cRGD-<z:chebi fb="77" ids="46793">PEG</z:chebi>-<z:chebi fb="0" ids="53231">PEI</z:chebi>/PEDF-pcDNA3.1 (+)-treated mice expressed more PEDF than that of the control groups </plain></SENT>
<SENT sid="6" pm="."><plain>Our study demonstrated that cRGD-<z:chebi fb="77" ids="46793">PEG</z:chebi>-<z:chebi fb="0" ids="53231">PEI</z:chebi> transported the PEDF gene into endothelia cells more efficiently than <z:chebi fb="77" ids="46793">PEG</z:chebi>-<z:chebi fb="0" ids="53231">PEI</z:chebi>, resulting in more effective inhibitory effects on <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> by anti-<z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>Therefore, for the first time, we have explored an effective non-<z:mp ids='MP_0001799'>viral</z:mp> vehicle for PEDF gene therapy by targeting endothelial cells </plain></SENT>
</text></document>